MBX Biosciences (MBX) EBT (2023 - 2026)

MBX Biosciences has reported EBT for 4 years, with the latest figure at -$102.0 million in Q1 2026.

• Quarterly EBT fell 277.35% year-over-year to -$102.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$213.7 million (down 181.93% YoY) and the FY2025 annual result came in at -$184.7 million, down 78.69% from the prior year.
• EBT slipped to -$102.0 million in Q1 2026 per MBX's latest filing, from -$14.9 million in the prior quarter.
• Over five years, EBT peaked at -$10.9 million in Q3 2023 and troughed at -$102.0 million in Q1 2026.
• A 4-year average of -$29.8 million and a median of -$16.8 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2024 and 2026: EBT gained 13.78% in 2024, then tumbled 277.35% in 2026.
• Over 4 years, EBT stood at -$14.5 million in 2023, then grew by 13.78% to -$12.5 million in 2024, then decreased by 19.43% to -$14.9 million in 2025, then slumped by 584.29% to -$102.0 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$102.0 million, -$14.9 million, and -$61.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.